Dose contribution from brachytherapy to the pelvic lymph nodal region during HDR image-guided brachytherapy - a study for rethinking modern volume-based planning

高剂量率图像引导近距离放射治疗中盆腔淋巴结区域的剂量贡献——一项重新思考现代基于体积的计划的研究

阅读:1

Abstract

BACKGROUND: Previous studies have evaluated nodal dose using Point-A prescriptions or variable dose rates. However, the impact of volume-based high-dose-rate (HDR) brachytherapy approaches remains less explored. In this study, we aimed to assess the dose contribution to the pelvic lymph nodes with volume-based (HR-CTV) prescription in comparison to point-A-based prescription during HDR brachytherapy in carcinoma cervix. This comparison has not been comprehensively evaluated in earlier literature, especially in the context of elective nodal contouring and HDR brachytherapy. MATERIALS AND METHODS: Thirty patients with carcinoma of the cervix [International Federation of Gynecology and Obstetrics (FIGO) stage IB2 or higher] were included for this retrospective study. Two plans were generated on each brachytherapy scan. The first plan (point-A-based) prescribed a dose of 7 Gy to point-A, while the second plan (HR-CTV-based) prescribed the dose to the HR-CTV. Dose volume histograms (DVH) parameters were compared between both the plans. RESULTS: HR-CTV-based plans registered safer doses to OARs. Both the plans showed noticeable dose contributions to the pelvic lymph node stations, particularly the obturator, internal iliac, and presacral stations, with the highest contribution observed in the obturator group. However, HR-CTV-based plans contributed lower doses to these nodal regions, approximately 1 Gy less to the internal iliac and obturator stations and 2 Gy less to the presacral station compared to point-A-based plans when D50 was considered. CONCLUSIONS: HR-CTV-based plans demonstrated recognizable dose contribution to lymph nodes, although lower than the contribution by point-A-based plans. However, this modest difference can be effectively compensated by optimizing the external beam radiotherapy (EBRT) dose while simultaneously maintaining safe organ at risk (OAR) doses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。